Antibody-mediated neuropsychiatric disorders - 05/01/22
Doi : 10.1016/j.jaci.2021.11.008
Josep Dalmau, MD, PhD, FAAN a, b, c, d, e, ⁎ 
, Francesc Graus, MD, PhD a
, Francesc Graus, MD, PhD a a Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain
b Department of Neurology, Hospital Clínic, University of Barcelona, Barcelona, Spain
c Centro de Investigación Biomédica en Red, Enfermedades Raras (CIBERER), Madrid, Spain
d Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
e Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
∗Corresponding author: Josep Dalmau, MD, PhD, FAAN, University of Barcelona, Casanova, 143, Floor 3a, Barcelona 08036, Spain.University of BarcelonaCasanova143, Floor 3aBarcelona08036Spain
Key words : Autoimmune, neuropsychiatric, encephalitis, NMDA receptor, antibodies, synaptic
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. Dalmau holds patents for the use of Ma2, NMDAR, GABAbR, GABAaR, DPPX and IgLON5 as autoantibody tests; receives royalties related to autoantibody tests from Athena Diagnostics and Euroimmun, Inc; and receives research support from SAGE Therapeutics, Inc. F. Graus holds a patent for the use of IgLON5 as an autoantibody test. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 1
P. 37-40 - janvier 2022 Retour au numéro
Article précédent
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases
- Cezmi A. Akdis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?